Bioorganic & Medicinal Chemistry Letters · 2018 · 16 citations · 18 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationHit-to-lead OptimizationHit-to-lead ProgressionLead Compound DesignLead DiscoveryNeurodegenerative Disease PharmacotherapyPotency OptimizationDopaminergic NeuronsLead ChemistryLeucine-rich Repeat Receptor-like KinasesLrrk2 MutationsMedicinal Chemistry ApplicationsMedicinal HeterocyclesParkinson's Disease PharmacotherapyPhysicochemical Properties
Parkinson's disease is a relatively common neurological disorder with incidence increasing with age. Present treatments merely alleviate the symptoms and do not alter the course of the disease, thus identification of disease modifying therapies represents a significant unmet medical need. Mutations in the LRRK2 gene are risk-factors for developing PD and it has been hypothesized that the increased kinase activity of certain LRRK2 mutants are responsible for the damage of the dopaminergic neurons, thus LRRK2 inhibitors offer the potential to target an underlying cause of the disease. In this communication, we describe hit-to-lead medicinal chemistry program on a novel series of 5-azaindazoles. Compound 1, obtained from high-throughput screening was optimized to a highly potent, selective series of molecules with promising DMPK properties. Introduction of heterocycles at the 3-position were found to significantly increase the potency and kinase selectivity, whilst changes to the 4-chlorobenzyl group improved the physicochemical properties. Our series was licensed to a major pharmaceutical company for further development.
18
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Alexander Zimprich, Saskia Biskup, Petra Leitner et al. · Neuron · 2004 · 3.1K citations · Full text
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Coro Paisán-Ruı́z, Shushant Jain, E. Whitney Evans et al. · Neuron · 2004 · 2.4K citations · Full text
Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2010 · 1K citations
The maximal affinity of ligands
Irwin D. Kuntz, K. Chen, Kim A. Sharp et al. · Proceedings of the National Academy of Sciences · 1999 · 845 citations
Jaclyn L. Henderson, Bethany L. Kormos, Matthew M. Hayward et al. · Journal of Medicinal Chemistry · 2014 · 182 citations · Full text